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The saga of bevacizumab in brain tumors has been ongoing for
many years. Despite encouraging initial reports targeting the vas-
cular endothelial growth factor (VEGF) pathway by a neutralizing
monoclonal antibody (bevacizumab) or a receptor tyrosine kinase
inhibitor (cediranib), the few subsequent controlled studies were
largely disappointing. Opportunities for adequate clinical investi-
gation with bevacizumab were missed or delayed for many years.
Nevertheless, these agents undoubtedly have a clinically mean-
ingful benefit in selected patients. However, we lack clinical or bio-
markers allowing identification of specific patients that benefit
from these therapies. The highly variable clinical practice reflects
the contradictory reports and the paucity of prospective and con-
trolled trials. The absence of adequate data also prevented regu-
latory approval in many countries, especially in the European
Union, thus preventing access to bevacizumab for patients. Nu-
merous basic questions remain unresolved years after the drug
has entered routine clinical use.1 Two reports analyzing retrospec-
tively large institutional databases on management of recurrent
glioblastoma appear in this issue of Neuro-Oncology,2,3 and two
pivotal prospective randomized trials on the use of bevacizumab
in newly diagnosed patients were recently reported.4,5 Thus, it is
timely to briefly review some of the available data and discuss
their limitations.
Dose and schedule
In 2005, a practicing oncologist from Texas first reported the use
of bevacizumab for recurrent glioma. She treated 21 patients with
a standard regimen of bevacizumab (5 mg/kg every other week)
and irinotecan (125 mg/m2 weekly) at doses previously estab-
lished for colorectal cancer and observed 9 responses and 11 dis-
ease stabilizations.6 For unclear reasons, in subsequent trials a
lower dose of irinotecan (125 mg/m2 every other week) was
used while the bevacizumab dose (10 mg/kg) was doubled.7 At
the same time the randomized AVAIL study showed that increas-
ing the dose of bevacizumab from a low 2.5 to 5 mg/kg per week
(7.5 mg/kg and 15 mg/kg q 3 weeks, respectively) failed to im-
prove outcome in non-small cell lung cancer.8 Bevacizumab’s
long terminal half-life of 21-27 days would allow for dosing inter-
vals of 3-4 weeks or longer. Some preclinical models suggest that
high doses of anti-angiogenic therapy may be detrimental
by inducing hypoxia and induce a more aggressive and invasive
phenotype;9–11 although, in one murine model, higher doses of
bevacizumab conferred a longer survival.12
Should bevacizumab be given in combination with
a cytotoxic agent?
Bevacizumab was the first anti-angiogenic and vasculature-
modifying agent entering the clinic in the treatment of solid
tumors. As a single agent it was without activity13; however,
in combination with cytotoxic chemotherapy (irinotecan/
5-fluorouracil) it prolonged survival in recurrent colorectal can-
cer,14,15 and in combination with cytotoxic therapy some activity
has also been demonstrated for non-small cell lung cancer,
breast cancer, and ovarian cancer. Thus, there is a strong, indirect
rationale to combine bevacizumab with cytotoxic chemotherapy
in glioma. The non-comparative randomized phase II BRAIN trial
examined bevacizumab alone and bevacizumab with irinotecan.7
Progression-free survival was somewhat prolonged with the com-
bination, but therewas no difference in overall survival. Irinotecan
is not an accepted active agent for recurrent glioblastoma, how-
ever. We lack truly active second-line cytotoxic chemotherapy
after temozolomide failure. The REGAL trial in recurrent glioblas-
toma was a randomized phase III trial comparing cediranib
(VEGFR-tyrosine kinase inhibitor (TKI) or the combination of cedir-
anib and lomustine (CCNU) with lomustine alone.16 The two
lomustine-containing arms showed a trend towards improved
outcome over cediranib alone; however, the combination of cedir-
anib and lomustine was not superior to lomustine alone. In a
small, Dutch randomized phase II trial improved survival was
suggested with the combination of bevacizumab and lomustine
vs lomustine or bevacizumab alone.17 This regimen is currently
being evaluated in a definitive phase III trial by the European
Organisation for Research and Treatment of Cancer (EORTC trial
26101, NCT#01290939). Thus, among a plethora of agents tested
in uncontrolled trials, only lomustine has provided a signal of ac-
tivity in combination with bevacizumab, and interestingly, lomus-
tine stands out somewhat by its intrinsic activity in the recurrent
setting. Of note, the combination of anti-angiogenic agents with
other pharmacological agents may require careful, preferentially
early sequencing studies, since the vascular normalization para-
digm is increasingly challenged and drug delivery may indeed be
inhibited by drugs like bevacizumab.18
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When and for how long should bevacizumab be given?
In this issue of Neuro-Oncology, Piccioni et al interrogated their
database of 468 patients treated with standard temozolomide
(TMZ) and radiotherapy (RT)19 who received bevacizumab upfront
or at the first or a later recurrence.3 Progression-free survival after
bevacizumab initiation of 4 months was similar whether bevaci-
zumab was initiated at first recurrence or at a later stage, leading
the authors to conclude that administration can safely be de-
ferred to a later stage in relatively asymptomatic patients. Simi-
larly, combination with a cytotoxic agent did not improve survival.
Puduvalli and colleagues report on their experience on 82 pa-
tients with recurrent glioblastoma who were responding or stable
on bevacizumab therapy for more than 6 months.2 In 18 patients
bevacizumab was discontinued early for reasons other than dis-
ease progression (eg toxicity, patient’s refusal) and the results
with these patients were compared with those of the 64 patients
who continued treatment until progression or beyond. Time to pro-
gression after bevacizumab discontinuation was 27 weeks. Impor-
tantly, at subsequent progression a sustained response was
obtained again in almost half of the patients (median PFS6 47%
[95%CI 23-94%], while only 5% of the patients who progressed
while receiving bevacizumab achieved subsequent disease stabili-
zation with salvage therapy (median PFS6 5% [95%CI:1-21%].
Preclinical data suggested synergy when bevacizumab was
combined with radiation. Two independent but similarly designed
randomized trials (AvaGlio, designed and sponsored by Roche/
Genentech, and RTOG0825, developed by the Radiation Therapy
Oncology Group) evaluated bevacizumab when given to newly di-
agnosed glioblastoma patients in conjunction with radiotherapy
and temozolomide. Bevacizumab was given from day 1 of TMZ/
RT (AvaGlio) or starting in the fourth week of TMZ/RT (RTOG
trial) at a dose of 10 mg/kg every other week and was to be con-
tinued until disease progression. Progression-free survival was
prolonged in both trials in the bevacizumab arms (median 10.7
vs 7.3 months in RTOG0525; 10.6 vs 6.2 months in AvaGlio); how-
ever, this did not translate into prolongation of overall survival.
Importantly, the median overall survival of 16 months is not sub-
stantially longer than the overall survival in prior TMZ-containing
trials. And despite the use of bevacizumab either upfront or at re-
currence, survival is comparable also to the pivotal EORTC/NCIC
trial19,20 conducted almost 10 years earlier which also included
biopsy-only patients (in the RTOG trials surgical tumor debulking
was mandatory). One may conclude that bevacizumab does not
substantially increase survival in glioblastoma, whether given
upfront or at recurrence. To date, no subgroup has been identified
that consistently benefits from VEGF inhibition, although elderly
patients may derive relatively more benefit.21
But isn’t a prolongation of progression-free survival a valuable
benefit in patients where disease progression is commonly asso-
ciated with debilitating neurological symptoms? Unfortunately,
there is uncertainty in determining progression based on radio-
logical findings alone, in the absence of clinical progression,
when using an agent that interferes with vessel permeability
and contrast enhancement. There is also uncertainty in the ef-
fects of bevacizumab on quality of life. Conclusions about quality
of life (AvaGlio) and net clinical benefit (RTOG0825) are contradic-
tory. While quality of life appears improved due to the delayed
progression in the experimental arm in AVAGlio, bevacizumab
appeared to decrease net clinical benefit (a composite of quality
of life and neurological function) in the RTOG study. A limitation of
both studies is that they discontinued evaluation of secondary
endpoints and quality of life at the time of tumor progression,
when evaluation of quality of life should ideally also cover the
period post-progression.
Controversy persists regarding whether bevacizumab should
be discontinued upon progression. Due to the lack of efficacious
salvage treatments and the fear of rebound, treatment with bev-
acizumab is commonly maintained beyond progression. There is
no data supporting this practice and the long half-life of bevaci-
zumab makes this a priori unlikely. Nevertheless, a rebound in
contrast enhancement and edema may be observed with the
waning effect of bevacizumab 6–8 weeks after discontinuation,
making evaluation of efficacy of subsequent treatments chal-
lenging. Conversely, rapid rebound within hours to days due to
the short half-life of VEGFR-TKI have been observed.16,22 Little
clinical benefit has been demonstrated with adding another
cytotoxic agent while continuing bevacizumab beyond progres-
sion.7,23,24 The ongoing Roche-sponsored randomized phase III
TAMIGA trial is evaluating the value of continuation of bevacizu-
mab for patients who have progressed following first-line therapy
with bevacizumab and TMZ/RTSTMZ (NCT#01860638).
In summary, we have made only very modest progress in the
management of glioblastoma over the last decade. A series of
prospective randomized trials failed to demonstrate significantly
improved outcome.4,5,16,25–27Bevacizumab and other VEGF path-
way inhibitors have consistently resulted in radiological reduction
in contrast enhancement, and peritumoral edema allowed for a
decrease in corticosteroid requirement.7,16,23 Nevertheless, short
of adequate clinical investigations we remain unable to identify
patients likely to benefit from bevacizumab. The commonly
used high doses of bevacizumab are associated with some, albeit
limited, toxicities, that may have contributed to the negative re-
sults in newly diagnosed patients with increased side effects and
a decrease in net clinical benefit. There may be value in reduced
utilization of corticosteroids and their inherent toxicity; however,
potential benefits related to reduction in steroids and improve-
ment in quality of life have never been investigated. Strategic er-
rors and omissions in a drug’s early developmental plan are
difficult to correct years later. Requirements needed for regulato-
ry approval may not match the clinical reality of the use of a drug
already on themarket. The retrospective investigations by Piccioni
and Puduvalli and other anecdotal experience suggest that bev-
acizumab should be used at a later time point in the course of the
disease,3 administered for a shorter time (e.g. 6 months only),2
and possibly at a lower dose,12 at least for themajority of patients
who are eligible for more than one line of treatment.
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